These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 39092594)

  • 21. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous immunotherapy with purified Der p1 and 2 suppresses type 2 immunity in a murine asthma model.
    Hesse L; van Ieperen N; Habraken C; Petersen AH; Korn S; Smilda T; Goedewaagen B; Ruiters MH; van der Graaf AC; Nawijn MC
    Allergy; 2018 Apr; 73(4):862-874. PubMed ID: 29318623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of adverse reactions induced by subcutaneous immunotherapy against dust mite allergy in 234 cases with allergic rhinitis and asthma].
    Li MR; Wang XN; Jiang HD; Wang QY; Li YC; Lin J; Jin K; Zhang HL; Li CC
    Zhonghua Er Ke Za Zhi; 2012 Oct; 50(10):726-31. PubMed ID: 23302557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, 5-arm dose finding study with a mite allergoid SCIT in allergic rhinoconjunctivitis patients.
    Pfaar O; Nell MJ; Boot JD; Versteeg SA; van Ree R; Roger A; Riechelmann H; Sperl A; Oude Elberink JN; Diamant Z; Bachert C
    Allergy; 2016 Jul; 71(7):967-76. PubMed ID: 26864207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety of subcutaneous immunotherapy with TO-204 in Japanese patients with house dust mite-induced allergic rhinitis and allergic bronchial asthma: Multicenter, open label clinical trial.
    Fujisawa T; Shimoda T; Masuyama K; Okubo K; Honda K; Okano M; Katsunuma T; Urisu A; Kondo Y; Odajima H; Kurihara K; Nagata M; Taniguchi M; Taniuchi S; Doi S; Matsumoto T; Hashimoto S; Tanaka A; Natsui K; Abe N; Ozaki H
    Allergol Int; 2018 Jul; 67(3):347-356. PubMed ID: 29233461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study.
    Jutel M; Klimek L; Richter H; Brüggenjürgen B; Vogelberg C
    Allergy; 2024 Apr; 79(4):1042-1051. PubMed ID: 38429981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.
    Eifan AO; Calderon MA; Durham SR
    Expert Opin Biol Ther; 2013 Nov; 13(11):1543-56. PubMed ID: 24099116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bronchial allergen provocation: a useful method to assess the efficacy of specific immunotherapy in children.
    Rosewich M; Arendt S; El Moussaoui S; Schulze J; Schubert R; Zielen S
    Pediatr Allergy Immunol; 2013 Aug; 24(5):434-40. PubMed ID: 23578317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens.
    Chen S; Zheng Y; Chen B; Zhong H; Liao F; Wang L; Hui SF; Lai X
    Int Arch Allergy Immunol; 2019; 178(2):201-210. PubMed ID: 30544116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of subcutaneous house dust mite immunotherapy in patients with moderate to severe allergic rhinitis.
    Valero A; Ibáñez-Echevarría E; Vidal C; Raducan I; Castelló Carrascosa JV; Sánchez-López J
    Immunotherapy; 2022 Jun; 14(9):683-694. PubMed ID: 35465692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of semi-depot house dust mite allergen extract in children and adolescents with allergic rhinitis and asthma.
    Xiang L; Liu F; Zhi L; Jiang W; Liu C; Xie H; Zhou X; Sun Y; Zheng Y; Zhu R; Tao Z; Xia W; Lai H; Wei Q; Cheng L; Tang Y; Xu R; Huang H; Zhou Q; Chang P
    Immunotherapy; 2021 Feb; 13(3):227-239. PubMed ID: 33317341
    [No Abstract]   [Full Text] [Related]  

  • 32. [Efficacy and safety study of standardized mite allergen specific immunotherapy with no reduction during maintenance in children with respiratory allergic disease].
    Liang Y; Zhong Y; Li YY; Zhu LP; Yang LF; Ou SX; Chen ZG; Zhang PP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Jun; 58(6):768-777. PubMed ID: 38955723
    [No Abstract]   [Full Text] [Related]  

  • 33. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
    Hesse L; Petersen AH; Nawijn MC
    Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy.
    Liu Y; Xing Z; Wang J; Geng C
    Am J Rhinol Allergy; 2018 Nov; 32(6):458-464. PubMed ID: 30124065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
    J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
    Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
    Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
    Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
    Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma.
    Zhang P; Jia Y; Jing Z; Huang J; Wu H; Sun X
    Pulm Pharmacol Ther; 2023 Feb; 78():102187. PubMed ID: 36603742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early Intervention Improves Clinical Responses to House Dust Mite Immunotherapy in Allergic Rhinitis Patients.
    Qi S; Chen H; Huang N; Li W; Liu G; Wang Y; Hu L; Wang X; Zhang W; Zhu R
    Int Arch Allergy Immunol; 2016; 171(3-4):234-240. PubMed ID: 28049194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and adverse reactions to subcutaneous immunotherapy in children with allergic rhinitis/asthma.
    Duman Senol H; Topyildiz E; Ekici B; Gulen F; Demir E
    Int J Pediatr Otorhinolaryngol; 2022 Nov; 162():111292. PubMed ID: 36007303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.